KaloBios Emerges From Ch. 11 With Chagas Drug Rights
Drug development company KaloBios Pharmaceuticals Inc. emerged from Chapter 11 Thursday using an $11 million exit facility to buy the rights to develop a drug used to treat Chagas disease in...To view the full article, register now.
Already a subscriber? Click here to view full article